These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19442087)

  • 1. Cellular transport and lipid interactions of miltefosine.
    Barratt G; Saint-Pierre-Chazalet M; Loiseau PM
    Curr Drug Metab; 2009 Mar; 10(3):247-55. PubMed ID: 19442087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hexadecylphosphocholine interaction with lipid monolayers.
    Rakotomanga M; Loiseau PM; Saint-Pierre-Chazalet M
    Biochim Biophys Acta; 2004 Mar; 1661(2):212-8. PubMed ID: 15003884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Membrane sterol depletion impairs miltefosine action in wild-type and miltefosine-resistant Leishmania donovani promastigotes.
    Saint-Pierre-Chazalet M; Ben Brahim M; Le Moyec L; Bories C; Rakotomanga M; Loiseau PM
    J Antimicrob Chemother; 2009 Nov; 64(5):993-1001. PubMed ID: 19749205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crossregulation between the insertion of Hexadecylphosphocholine (miltefosine) into lipid membranes and their rheology and lateral structure.
    Zulueta Díaz YLM; Fanani ML
    Biochim Biophys Acta Biomembr; 2017 Oct; 1859(10):1891-1899. PubMed ID: 28642044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions.
    Rakotomanga M; Saint-Pierre-Chazalet M; Loiseau PM
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2677-86. PubMed ID: 15980336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inward translocation of the phospholipid analogue miltefosine across Caco-2 cell membranes exhibits characteristics of a carrier-mediated process.
    Ménez C; Buyse M; Farinotti R; Barratt G
    Lipids; 2007 Apr; 42(3):229-40. PubMed ID: 17393228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites.
    Pérez-Victoria FJ; Sánchez-Cañete MP; Castanys S; Gamarro F
    J Biol Chem; 2006 Aug; 281(33):23766-75. PubMed ID: 16785229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.
    Rakotomanga M; Blanc S; Gaudin K; Chaminade P; Loiseau PM
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1425-30. PubMed ID: 17242145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB.
    Fleer EA; Berkovic D; Grunwald U; Hiddemann W
    Eur J Cancer; 1996 Mar; 32A(3):506-11. PubMed ID: 8814699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug.
    Pérez-Victoria FJ; Castanys S; Gamarro F
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2397-403. PubMed ID: 12878496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of resistance in the human leukemia cell line HL60 towards hexadecylphosphocholine and other ether phospholipid analogues.
    Berkovic D; Haase D; Hiddemann W; Fleer EA
    J Exp Ther Oncol; 1996 Nov; 1(6):368-75. PubMed ID: 9414427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of release and pharmacokinetics of hexadecylphosphocholine (miltefosine) in phosphatidyldiglycerol-based thermosensitive liposomes.
    Rysin A; Paal M; Lokerse WJM; Wedmann B; Hossann M; Vogeser M; Winter G; Lindner LH
    Biochim Biophys Acta Biomembr; 2021 Nov; 1863(11):183698. PubMed ID: 34283999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance.
    Pérez-Victoria FJ; Gamarro F; Ouellette M; Castanys S
    J Biol Chem; 2003 Dec; 278(50):49965-71. PubMed ID: 14514670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual role of hexadecylphosphocholine (miltefosine) in thermosensitive liposomes: active ingredient and mediator of drug release.
    Lindner LH; Hossann M; Vogeser M; Teichert N; Wachholz K; Eibl H; Hiddemann W; Issels RD
    J Control Release; 2008 Jan; 125(2):112-20. PubMed ID: 18022271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes.
    Luque-Ortega JR; Rivas L
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1327-32. PubMed ID: 17283192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interference effects of hexadecylphosphocholine on proliferation and membrane phospholipid metabolism in human myeloid leukemia cell lines.
    Wang YZ; Chang YB; Xing C; Fu D
    Int J Tissue React; 1998; 20(3):101-7. PubMed ID: 9894183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
    Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Miltefosine inhibits the membrane remodeling caused by phospholipase action by changing membrane physical properties.
    Zulueta Díaz YLM; Ambroggio EE; Fanani ML
    Biochim Biophys Acta Biomembr; 2020 Oct; 1862(10):183407. PubMed ID: 32628918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of intestinal barrier properties by miltefosine.
    Menez C; Buyse M; Chacun H; Farinotti R; Barratt G
    Biochem Pharmacol; 2006 Feb; 71(4):486-96. PubMed ID: 16337152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations.
    Papagiannaros A; Bories C; Demetzos C; Loiseau PM
    Biomed Pharmacother; 2005 Dec; 59(10):545-50. PubMed ID: 16325367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.